Chemerin Promotes the Pathogenesis of Preeclampsia by Activating RBP-J/miR-182-5p/CEBPɑ/IRF8 Pathway and Inducing M1 Macrophage Polarization
Zhi-Song Ji,Hua Jiang,Yue Xie,Qi-Peng Wei,Xiao-Fang Yin,Jin-Hai Ye,Xiao-Zhen Quan,Yan-Li Lan,Meng Zhao,Xiao-Long Tian,Ya-Jun Zhang,Xue-Zhou Yang
DOI: https://doi.org/10.2139/ssrn.3667639
2020-01-01
Abstract:Background: To examine the significance RBPJ/miR-182-5p/CEBPα/IRF8 axis in mediating the pathogenic effects of chemerin on preeclampsia.Methods: The biological phenotypes examined included surface expressions of CD80 and CD86 on macrophages by flow cytometry, productions of IL-10 and IL-12 by ELISA, macrophage-induced trophoblast invasion/migration and angiogenesis by Transwell/wound healing assay and tube formation assay, and expressional analysis of trophoblast markers, angiogenesis markers, as well as different signaling molecules by RT-qPCR or Western blot. The specific targeting of miR-182-5p on CEBPα and of CEBPα on IRF8 was examined by combining luciferase assay, ChIP, EMSA, and RIP. Lastly, the in vivo effects of chemerin and blocking chemerin signaling were examined using a rat preeclampsia model. Findings: Chemerin promoted M1 macrophage polarization, inhibited macrophage-induced trophoblast invasion and migration, and suppressed macrophage-mediated angiogenesis. RBPJ, miR-182-5p, CEBPα and IRF8 all essentially mediated the effects of chemerin on macrophage polarization, trophoblast invasion and migration, and angiogenesis. Mechanistically, RBPJ inhibited the expression of miR-182-5p, which directly targeted CEBPα. CEBPα acted as a transcriptional activator for IRF8. In vivo, chemerin aggravated preeclampsia while α-NETA, an inhibitor for chemerin receptor, significantly suppressed M1 macrophage polarization and alleviated preeclampsia.Interpretation: Chemerin, by activating the RBPJ/miR-182-5p/CEBPα/IRF8 axis, promotes M1 macrophage polarization, suppresses trophoblast invasion and migration, or angiogenesis, and contributes to preeclampsia.Funding: This work was supported by the Natural Science Foundation of Hubei(2018CFB472) and Special Fund for Young and Middle-aged Research of Luo yuankai (20190808).Declaration of Interests: The authors declare no competing financial interests.Ethics Approval Statement: The study has been approved by the Ethic Committee of Xiangyang Central Hospital.